Latest studies
- RecruitingPHASE3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
This study looks at a new medicine called Tozorakimab. We want to see if it can help people in hospital with lung infections who need extra oxygen. The goal is to stop them from getting sicker, like needing a breathing machine, or even dying.
Viral Lung Infection and Acute Respiratory FailureDenmark - Active not recruitingPHASE2
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
This study is for adults with bronchiectasis who were in a previous trial with the medicine BI 1291583. It aims to see if this medicine helps long-term and how well people tolerate it. Participants take tablets daily and visit the clinic regularly.
BronchiectasisDenmark - RecruitingPHASE3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
This study is testing a new drug, neladalkib, for people with a common type of lung cancer (NSCLC) that's ALK-positive. It's comparing neladalkib to a standard treatment, alectinib, to see if neladalkib works better at stopping the cancer from growing.
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positiveDenmark - RecruitingPHASE3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
This study is looking at a new treatment (BNT323) for women with advanced womb cancer that has come back. It compares BNT323 to standard chemotherapy to see if it works better at shrinking tumours and keeping the cancer from growing.
Endometrial CancerDenmark - Enrolling by invitationPHASE3
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
This study looks at a new medicine called efgartigimod for people with certain muscle conditions like myositis. It's for adults who were in a previous study, to see if the medicine is safe and helpful over a long time.
MyositisActive Idiopathic Inflammatory MyopathyDermatomyositisPolymyositisDenmark - RecruitingPHASE2
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
This study looks at whether a new medicine, BI 764198, can help adults and teenagers with certain kidney problems. It compares the new medicine to a dummy pill to see if it reduces protein in the urine and improves kidney health.
Proteinuric Kidney DiseasesDenmark - RecruitingPHASE3
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
This study is looking into a new drug, AZD5335, for women with advanced ovarian cancer that has become resistant to usual chemotherapy. It compares AZD5335 to existing treatments to see if it works better at controlling the cancer's growth.
Epithelial Ovarian CancerDenmark - RecruitingPHASE2
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
This study is testing a new medicine, efgartigimod, for adults with systemic sclerosis. It aims to see if the medicine helps improve symptoms and if it's safe, compared to a dummy medicine. We're looking for people to join for about 15 months.
Systemic Sclerosis (SSc)Denmark - Active not recruitingNA
Portico Next Generation Approval Study
This study is testing a new replacement heart valve, called Portico™ NG, for people with severe aortic stenosis who are very sick or at high risk for surgery. It aims to make sure the new valve is safe and works well to improve their heart condition.
Symptomatic Severe Aortic StenosisDenmark - RecruitingPHASE3
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
This study is testing if combining two targeted therapies, belzutifan and zanzalintinib, works better than belzutifan alone for advanced kidney cancer. Researchers want to see if this combination helps people live longer and keeps the cancer from getting worse.
Carcinoma, Renal CellDenmark - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
This study is for people with advanced HR+/HER2- breast cancer. It compares a new drug, sacituzumab tirumotecan (alone or with pembrolizumab), against standard chemotherapy, to see which treatment best controls the cancer's growth.
Breast NeoplasmsDenmark - RecruitingPHASE4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
This study looks at whether blood-thinning medicines (anticoagulants) can prevent strokes and other heart-related problems in people who have had temporary episodes of an irregular heartbeat called atrial fibrillation (AF) during stressful times like surgery or serious illness.
StrokeAtrial FibrillationDenmark - RecruitingPHASE2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
This study is testing a new drug, nemtabrutinib, for people with certain blood cancers like lymphoma and leukaemia. It aims to see if the drug is safe and effective in treating these conditions.
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins LymphomaChronic Lymphocytic LeukaemiaDenmark - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
This study looks at new treatments, sacituzumab tirumotecan alone or with pembrolizumab, for triple-negative breast cancer. It compares their effectiveness with standard chemotherapy to see if they help people live longer or stop cancer growth.
Triple Negative Breast NeoplasmsDenmark - RecruitingPHASE3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
This study looks at a new drug, Surovatamig, combined with rituximab, for people with previously untreated follicular lymphoma. It compares this new combination therapy with standard treatments to see if it works better and is safe.
Untreated Follicular LymphomaDenmark - Active not recruitingPHASE3
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
This study looks at new treatments for HER2-positive breast cancer that has spread. It compares an experimental drug, trastuzumab deruxtecan (T-DXd), alone or with another drug, pertuzumab, to standard care, to see if they work better and are safe.
Breast Cancer; HER2-positive; MetastaticDenmark - RecruitingPHASE3
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
This study looks at a new medicine called lebrikizumab for people with chronic rhinosinusitis and nasal polyps, who are already using nasal sprays. It aims to see how well it works and if it's safe over about 18 months.
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Denmark - RecruitingPHASE3
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
This study is looking at a new medicine called INCB161734, given alongside standard chemotherapy, for advanced pancreatic cancer with a specific genetic change (KRAS G12D). It aims to see if this combination works better and is safe for people who haven't had treatment for their advanced cancer.
Solid TumorsDenmark - RecruitingPHASE3
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
This study is for women with advanced ovarian cancer that has responded well to initial treatment. It's testing a new medicine called sac-TMT, sometimes with bevacizumab, to see if it can keep the cancer from growing or coming back for longer than standard care.
Ovarian NeoplasmsOvarian CancerDenmark - RecruitingPHASE3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
This study looks at a new medicine called muvalaplin to see if it can lower the risk of heart attacks and strokes in people with high levels of a specific fat in their blood called Lp(a).
Elevated Lp(a)Atherosclerotic Cardiovascular Disease (ASCVD)Denmark - RecruitingPHASE2
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
This study is looking into a new medicine, calderasib, to treat certain advanced cancers. Researchers want to see if it can shrink these cancers, either alone or with another medicine called cetuximab, in people whose cancers have a specific genetic change (KRAS G12C mutation).
Neoplasm MalignantDenmark - RecruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
Non-small Cell Lung CancerDenmark - RecruitingPHASE3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
This study compares a new medicine called nemtabrutinib with existing treatments (ibrutinib or acalabrutinib) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. The aim is to see if the new drug is as good or better.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaDenmark - Active not recruitingPHASE3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
This study is looking at a new medicine called frexalimab for people aged 18-55 with certain types of Multiple Sclerosis (MS). It compares frexalimab to an existing MS medicine, teriflunomide, to see how well it stops MS relapses and if it's safe.
Multiple SclerosisDenmark - RecruitingPHASE3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
This study looks at the long-term effects of a medicine called belzutifan for people with advanced cancers or cancers linked to Von Hippel-Lindau disease. It's for those already taking belzutifan in other trials. The aim is to see how long people live after starting this treatment.
Von Hippel-Lindau DiseaseMalignant NeoplasmsDenmark - RecruitingPHASE3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
This study is looking into a new medication called AZD0780. It aims to see if this medicine can lower the risk of serious heart problems like heart attacks or strokes in people who have already had them, or in those at high risk of having one for the first time.
Cardiovascular DiseaseDenmark - RecruitingPHASE3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
This study looks at combining two medicines, mirikizumab and tirzepatide, for adults with ulcerative colitis (UC) who are also overweight or obese. The goal is to see if this combination helps UC symptoms improve and also leads to significant weight loss.
Ulcerative ColitisObesity or OverweightDenmark - RecruitingPHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
This study looks at a new drug, olomorasib, combined with other treatments for advanced lung cancer. It’s for people whose cancer has a specific change called KRAS G12C and haven't had previous treatment for advanced disease. The aim is to see if this new combination works better than standard care.
Carcinoma, Non-Small-Cell LungNeoplasm MetastasisDenmark - RecruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
This study is looking at a new combination of treatments for advanced lung cancer. It compares giving two drugs together (sacituzumab tirumotecan and pembrolizumab) against giving pembrolizumab on its own, to see if the combination helps people live longer.
Non-small Cell Lung Cancer (NSCLC)Denmark - Active not recruitingPHASE3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
This study looks at whether a new medicine, retatrutide, can help adults with obesity who also have heart disease or kidney problems. It aims to see if the medicine can reduce serious heart issues or stop kidney problems from getting worse.
Atherosclerotic Cardiovascular Disease (ASCVD)Chronic Kidney Disease (CKD)Denmark - RecruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This study looks at a new drug combination, sacituzumab tirumotecan and pembrolizumab, for a type of breast cancer called triple-negative. It's for patients who had initial treatment but still have some cancer cells after surgery. We want to see if this new combination helps prevent the cancer from coming back better than standard care.
Triple-Negative Breast CancerDenmark - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
This study looks at a new treatment called sacituzumab tirumotecan, sometimes with another medicine called bevacizumab. We want to see if it's safe and helps women with ovarian, fallopian tube, or primary peritoneal cancer live longer without their cancer getting worse, compared to standard care.
Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerDenmark - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
Metastatic Non-small Cell Lung Cancer With MTAP DeletionDenmark - RecruitingPHASE1, PHASE2
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
This study is looking into a new drug, AZD3632, for certain blood cancers like leukaemia and myelodysplastic syndromes. It aims to check its safety, how well it works, and how the body handles it, both on its own and with another medicine.
Acute Lymphoblastic LeukaemiaAcute Myeloid LeukaemiaHigher-risk Myelodysplastic SyndromesDenmark - Active not recruitingPHASE3
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
This study looks at a new drug, lepodisiran, to help people with high lipoprotein(a) reduce their risk of heart attacks and strokes. It's for adults with existing heart disease or those at high risk. The drug is given as an injection under the skin.
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)Denmark - RecruitingPHASE2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This study is testing a new medicine called belzutifan for certain types of advanced cancers, including rare adrenal gland, gut, and kidney cancers. We want to see how well it works and if it's safe for people aged 12 and over.
Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau DiseaseAdvanced Gastrointestinal Stromal TumorDenmark - RecruitingPHASE1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
This study looks at new treatments for bowel cancer that has spread. We want to see if these targeted medicines or immunotherapy are safe and work well for people whose cancer has specific genetic features, which we call biomarkers.
Metastatic Colorectal CancerDenmark - Active not recruitingPHASE2
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
This study is looking into a new medication called ESK-001 for adults with an active form of lupus (SLE). We want to see if it's safe and helps improve symptoms compared to a dummy drug (placebo).
SLEDenmark - RecruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
This study looks at new treatments for a type of womb cancer that has spread or returned. It compares a new drug combination (sac-TMT with pembrolizumab) against pembrolizumab alone to see if it helps patients live longer and keeps the cancer from growing.
Endometrial CancerDenmark - RecruitingPHASE1, PHASE2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
This study is testing a new medicine called S241656 for people with certain advanced cancers, including lung, bowel, and pancreatic cancers. It aims to find a safe and effective dose, either alone or with other treatments, for cancers with specific genetic changes.
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosisBRAF Gene MutationDenmark - RecruitingPHASE2
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
This study is looking into a new drug, AZD8965, for people with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if different doses of this drug are safe and effective, compared to a dummy drug, for people with IPF, including those already on other treatments.
Idiopathic Pulmonary Fibrosis (IPF)Denmark - Active not recruitingPHASE3
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
This study, called REDEFINE 3, investigates a new medicine, CagriSema, for people with heart and blood vessel diseases. It aims to see if CagriSema can reduce the risk of serious events like heart attacks and strokes.
Cardiovascular DiseaseDenmark - RecruitingPHASE2
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
This study is testing a new medicine, Vamifeport, for people with a common type of iron overload called hereditary hemochromatosis. It aims to see if the medicine can reduce the amount of iron stored in the liver. Two groups will be compared: one getting the medicine and one getting a dummy pill.
Homeostatic Iron Regulator Gene-related Hereditary HemochromatosisDenmark - Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
This study looks at how ATTR amyloidosis affects people in real life. Researchers will collect information from existing medical records to understand how the condition progresses, how it's treated, and its impact on daily life and healthcare use.
ATTR AmyloidosisDenmark - RecruitingPHASE3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
This study is testing a new medicine, ifinatamab deruxtecan (I-DXd), for men with advanced prostate cancer that has spread and isn't responding to hormone therapy. We want to see if I-DXd helps men live longer and keeps their cancer from growing compared to standard chemotherapy.
Prostate CancerProstatic NeoplasmsDenmark - RecruitingPHASE3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
This study is looking into a new medicine called Seladelpar for people with a liver condition called Primary Biliary Cholangitis (PBC) and mild liver scarring (cirrhosis). It aims to see how well Seladelpar works compared to a dummy pill to improve health outcomes.
Primary Biliary CholangitisDenmark - RecruitingPHASE1, PHASE2
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
This study is looking for new ways to treat specific childhood cancers that have come back or not responded to previous treatments. It investigates a new medicine called HER3-DXd (also known as patritumab deruxtecan) for safety and effectiveness in children aged 1 month to 17 years with hepatoblastoma or rhabdomyosarcoma.
Malignant NeoplasmDenmark - RecruitingPHASE3
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
This study is looking at a new medicine called axatilimab, alongside standard steroids, for people with chronic graft-versus-host disease (cGVHD). It compares axatilimab with a dummy medicine (placebo) to see how well it works to treat this condition.
Chronic Graft-versus-host-diseaseDenmark - RecruitingPHASE1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
This study is looking at a new medicine, AMG 410, for cancers with a specific change called KRAS. We want to see how safe it is, how it works in the body, and if it helps shrink tumors, both on its own and with other medicines.
KRAS Altered Advanced or Metastatic Solid TumorsDenmark - Recruiting
Product Surveillance Registry
This study keeps track of how well Medtronic medical devices, like those for heart problems or other conditions, work in real life. It aims to make sure these devices are safe and effective for patients.
Cardiac Rhythm DisordersUrological DisordersNeurological DisordersCardiovascular DisordersDenmark